Radiolabeled Study of AG-221 in Healthy Male Subjects.
- First Posted Date
- 2015-05-13
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- Celgene
- Target Recruit Count
- 8
- Registration Number
- NCT02443168
Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis
- First Posted Date
- 2015-05-06
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Celgene
- Target Recruit Count
- 1012
- Registration Number
- NCT02435992
- Locations
- 🇺🇸
Arizona Digestive Health, Sun City, Arizona, United States
🇺🇸Arkansas Gastroenterology, P.A., North Little Rock, Arkansas, United States
🇺🇸Medical Research Center of Connecticut, LLC, Hamden, Connecticut, United States
Relative Bioavailability Study of CC-292
- First Posted Date
- 2015-05-05
- Last Posted Date
- 2020-08-13
- Lead Sponsor
- Celgene
- Target Recruit Count
- 24
- Registration Number
- NCT02433457
- Locations
- 🇺🇸
Covance Clinical Research unit, Evansville, Indiana, United States
A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.
- Conditions
- Lymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin
- Interventions
- First Posted Date
- 2015-04-15
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Celgene
- Target Recruit Count
- 75
- Registration Number
- NCT02417285
- Locations
- 🇳🇱
Local Institution - 201, Amsterdam, Netherlands
🇳🇱Local Institution - 202, Rotterdam, Netherlands
🇫🇷Local Institution - 105, Borddeaux Cedex, France
A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell
- Interventions
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2021-09-20
- Lead Sponsor
- Celgene
- Target Recruit Count
- 47
- Registration Number
- NCT02406742
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇦🇹University Hospital of Salzburg St Johanns Spital, Salzburg, Austria
🇺🇸The West Clinic, Memphis, Tennessee, United States
Quality of Life in Metastatic Breast Cancer (MBC) Patients in Second Line Monochemotherapy
- Conditions
- Breast Neoplasms
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Celgene
- Target Recruit Count
- 149
- Registration Number
- NCT02403869
- Locations
- 🇪🇸
Hospital Virgen de Valme, Sevilla, Andalucía, Spain
🇪🇸Hospital Juan Ramón Jiménez, Huelva, Andalucía, Spain
🇪🇸Hospital Universitario Son Espases, Palma Mallorca, Baleares, Spain
Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Celgene
- Target Recruit Count
- 85
- Registration Number
- NCT02400242
- Locations
- 🇺🇸
Gabrail Cancer Center Research, Canton, Ohio, United States
🇺🇸University of Miami Medical Center, Miami, Florida, United States
🇺🇸Local Institution - 104, Boston, Massachusetts, United States
Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma
- Conditions
- Multiple Myeloma
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- Celgene
- Target Recruit Count
- 415
- Registration Number
- NCT02394210
- Locations
- 🇪🇸
Hospital Miguel Servet, Zaragoza, Aragón, Spain
🇪🇸Hospital Royo Villanova, Zaragoza, Aragón, Spain
🇪🇸Hospital Son Llatzer, Palma de Mallorca, Baleares, Spain
PK and Safety Study of AG-221 in Healthy Male Japanese Subjects and Healthy Male Caucasian Subjects
- First Posted Date
- 2015-03-13
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- Celgene
- Target Recruit Count
- 62
- Registration Number
- NCT02387866
- Locations
- 🇺🇸
Parexel International, Glendale, California, United States
A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TR
- Conditions
- Multiple Myeloma
- First Posted Date
- 2015-03-13
- Last Posted Date
- 2019-09-26
- Lead Sponsor
- Celgene
- Target Recruit Count
- 500
- Registration Number
- NCT02387879
- Locations
- 🇹🇷
Baskent University Adana Application and Research Hospital, Adana, Turkey
🇹🇷Cukurova University Medical Faculty, Adana, Turkey
🇹🇷Ankara University Medical Faculty, Ankara, Turkey